Cargando…
Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
BACKGROUND: The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with SEA, we lack data on a possib...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613971/ https://www.ncbi.nlm.nih.gov/pubmed/37908397 http://dx.doi.org/10.1183/23120541.00419-2023 |
_version_ | 1785128941050134528 |
---|---|
author | Portacci, Andrea Campisi, Raffaele Buonamico, Enrico Nolasco, Santi Pelaia, Corrado Crimi, Nunzio Benfante, Alida Triggiani, Massimo Spadaro, Giuseppe Caiaffa, Maria Filomena Scioscia, Giulia Detoraki, Aikaterini Valenti, Giuseppe Papia, Francesco Tomasello, Alessandra Scichilone, Nicola Pelaia, Girolamo Crimi, Claudia Carpagnano, Giovanna Elisiana |
author_facet | Portacci, Andrea Campisi, Raffaele Buonamico, Enrico Nolasco, Santi Pelaia, Corrado Crimi, Nunzio Benfante, Alida Triggiani, Massimo Spadaro, Giuseppe Caiaffa, Maria Filomena Scioscia, Giulia Detoraki, Aikaterini Valenti, Giuseppe Papia, Francesco Tomasello, Alessandra Scichilone, Nicola Pelaia, Girolamo Crimi, Claudia Carpagnano, Giovanna Elisiana |
author_sort | Portacci, Andrea |
collection | PubMed |
description | BACKGROUND: The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with SEA, we lack data on a possible super-response to biologic treatments in patients suffering from these two diseases. We aim to assess super-responder features in real-life patients with SEA and EGPA treated with mepolizumab and benralizumab. METHODS: We enrolled 39 patients with SEA and EGPA eligible for treatment with mepolizumab or benralizumab. Super-responder assessment was performed considering oral corticosteroid (OCS) cessation, lack of exacerbations, forced expiratory volume in 1 s and Asthma Control Test (ACT) improvement. RESULTS: Super-responders showed worse clinical baseline characteristics than non-super-responder patients, with a greater improvement in severe asthma exacerbations, OCS dose reduction and ACT score increase. Definition of super-responders was consistent only considering a 12-month course of monoclonal antibody, lacking sensitivity in earlier evaluations. CONCLUSION: Mepolizumab and benralizumab are safe and effective in patients with EGPA and SEA, since a consistent proportion of patients show a super-response after 12 months of treatment. Further studies will address specific criteria for super-responder assessment in these patients. |
format | Online Article Text |
id | pubmed-10613971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-106139712023-10-31 Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis Portacci, Andrea Campisi, Raffaele Buonamico, Enrico Nolasco, Santi Pelaia, Corrado Crimi, Nunzio Benfante, Alida Triggiani, Massimo Spadaro, Giuseppe Caiaffa, Maria Filomena Scioscia, Giulia Detoraki, Aikaterini Valenti, Giuseppe Papia, Francesco Tomasello, Alessandra Scichilone, Nicola Pelaia, Girolamo Crimi, Claudia Carpagnano, Giovanna Elisiana ERJ Open Res Original Research Articles BACKGROUND: The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with SEA, we lack data on a possible super-response to biologic treatments in patients suffering from these two diseases. We aim to assess super-responder features in real-life patients with SEA and EGPA treated with mepolizumab and benralizumab. METHODS: We enrolled 39 patients with SEA and EGPA eligible for treatment with mepolizumab or benralizumab. Super-responder assessment was performed considering oral corticosteroid (OCS) cessation, lack of exacerbations, forced expiratory volume in 1 s and Asthma Control Test (ACT) improvement. RESULTS: Super-responders showed worse clinical baseline characteristics than non-super-responder patients, with a greater improvement in severe asthma exacerbations, OCS dose reduction and ACT score increase. Definition of super-responders was consistent only considering a 12-month course of monoclonal antibody, lacking sensitivity in earlier evaluations. CONCLUSION: Mepolizumab and benralizumab are safe and effective in patients with EGPA and SEA, since a consistent proportion of patients show a super-response after 12 months of treatment. Further studies will address specific criteria for super-responder assessment in these patients. European Respiratory Society 2023-10-30 /pmc/articles/PMC10613971/ /pubmed/37908397 http://dx.doi.org/10.1183/23120541.00419-2023 Text en Copyright ©The authors 2023 https://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. |
spellingShingle | Original Research Articles Portacci, Andrea Campisi, Raffaele Buonamico, Enrico Nolasco, Santi Pelaia, Corrado Crimi, Nunzio Benfante, Alida Triggiani, Massimo Spadaro, Giuseppe Caiaffa, Maria Filomena Scioscia, Giulia Detoraki, Aikaterini Valenti, Giuseppe Papia, Francesco Tomasello, Alessandra Scichilone, Nicola Pelaia, Girolamo Crimi, Claudia Carpagnano, Giovanna Elisiana Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
title | Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
title_full | Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
title_fullStr | Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
title_full_unstemmed | Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
title_short | Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
title_sort | real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613971/ https://www.ncbi.nlm.nih.gov/pubmed/37908397 http://dx.doi.org/10.1183/23120541.00419-2023 |
work_keys_str_mv | AT portacciandrea realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT campisiraffaele realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT buonamicoenrico realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT nolascosanti realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT pelaiacorrado realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT criminunzio realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT benfantealida realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT triggianimassimo realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT spadarogiuseppe realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT caiaffamariafilomena realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT sciosciagiulia realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT detorakiaikaterini realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT valentigiuseppe realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT papiafrancesco realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT tomaselloalessandra realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT scichilonenicola realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT pelaiagirolamo realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT crimiclaudia realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis AT carpagnanogiovannaelisiana realworldcharacteristicsofsuperresponderstomepolizumabandbenralizumabinsevereeosinophilicasthmaandeosinophilicgranulomatosiswithpolyangiitis |